


**CUMULATIVE
SUPPLEMENT 3
March 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 3

March 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 3
March 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> (FORMER ABBREVIATED NAME)	<u>NEW APPLICANT NAME</u> (NEW ABBREVIATED NAME)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711			
SINGLE SOURCE	2451	2446			
	(16.9%)	(16.6%)			
MULTISOURCE	11953	12187			
	(82.5%)	(82.8%)			
THERAPEUTICALLY EQUIVALENT	11792	12037			
	(81.4%)	(81.8%)			
NOT THERAPEUTICALLY EQUIVALENT	161	150			
	(1.1%)	(1.0%)			
EXCEPTIONS ¹	76	78			
	(0.5%)	(0.5%)			
NEW MOLECULAR ENTITIES APPROVED	6	8			
NUMBER OF APPLICANTS	810	826			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.
CFTG Change. A first time generic for the innovator product. A
TE Code is added.
CMFD Change. The product is moved from the Discontinued Section
due to a change in marketing status.
CMS1 Change. Miscellaneous addition to list.
CMS2 Change. Miscellaneous deletion from list.
CPOT Change. Potency amount/unit.
CRLD Change. Reference Listed Drug.
CTEC Change. Therapeutic Equivalence Code.
CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not
being marketed and will be moved to the discontinued
section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

	+ VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
--	-----------	--------------------	-------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
>A>	AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
>A>	AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
>A>	AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
-----	----	-------------	--------------	-------------	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

>D>	AP	TEVA PARENTERAL	3MG/ML	A078676 001	Jul 31, 2008	Mar	DISC
>A>		@	3MG/ML	A078676 001	Jul 31, 2008	Mar	DISC
		@	3MG/ML	A076564 001	Jun 16, 2004	Jan	DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076973 001	Jul 12, 2005	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

>A>	TABLET, EFFERVESCENT; ORAL						
-----	----------------------------	--	--	--	--	--	--

>A>	BINOSTO						
-----	---------	--	--	--	--	--	--

>A>	+ MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA
-----	------------------	--------------	---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
--	--------------------------------	--	--	--	--	--	--

ALFUZOSIN HYDROCHLORIDE

AB	INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
----	----------------	------	---------	-----	--------------	-----	------

>D> ALGLUCERASE

>D>	INJECTABLE; INJECTION						
-----	-----------------------	--	--	--	--	--	--

>D>	CEREDASE						
-----	----------	--	--	--	--	--	--

>D>	+ GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
-----	-----------	-------------	---------	-----	--------------	-----	------

>A>	@	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
-----	---	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

	TABLET, EXTENDED RELEASE; ORAL						
--	--------------------------------	--	--	--	--	--	--

ALPRAZOLAM

>D>	AB	SANDOZ	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
-----	----	--------	-------	---------	-----	--------------	-----	------

>D>	AB		1MG	A077777	002	Jun 30, 2006	Mar	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		2MG	A077777	003	Jun 30, 2006	Mar	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		3MG	A077777	004	Jun 30, 2006	Mar	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	@ SANDOZ INC		0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
-----	--------------	--	-------	---------	-----	--------------	-----	------

>A>	@		1MG	A077777	002	Jun 30, 2006	Mar	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

>A>	@		2MG	A077777	003	Jun 30, 2006	Mar	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

>A>	@		3MG	A077777	004	Jun 30, 2006	Mar	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

	TABLET, ORALLY DISINTEGRATING; ORAL						
--	-------------------------------------	--	--	--	--	--	--

NIRAVAM

AB	UCB INC	0.25MG	N021726	001	Jan 19, 2005	Jan	CAHN
----	---------	--------	---------	-----	--------------	-----	------

AB		0.5MG	N021726	002	Jan 19, 2005	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB	+	1MG	N021726	003	Jan 19, 2005	Jan	CAHN
----	---	-----	---------	-----	--------------	-----	------

AB		2MG	N021726	004	Jan 19, 2005	Jan	CAHN
----	--	-----	---------	-----	--------------	-----	------

ALVIMOPAN

	CAPSULE; ORAL						
--	---------------	--	--	--	--	--	--

ENTEREG

	+ CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Feb	CAHN
--	-----------------	------	---------	-----	--------------	-----	------

AMCINONIDE

	CREAM; TOPICAL						
--	----------------	--	--	--	--	--	--

AMCINONIDE

AB	+ FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN
----	------------------	------	---------	-----	--------------	-----	------

	LOTION; TOPICAL						
--	-----------------	--	--	--	--	--	--

AMCINONIDE

	+ FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
--	------------------	------	---------	-----	--------------	-----	------

	OINTMENT; TOPICAL						
--	-------------------	--	--	--	--	--	--

AMCINONIDE

AB	+ FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	------------------	------	---------	-----	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

>A>	AMINO ACIDS						
>A>	B BRAUN	15% (150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA	
>A>		15% (300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA	
	NOVAMINE 15%						
>D>	@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT	
>A>	@	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT	

AMINOCAPROIC ACID

INJECTABLE; INJECTION

	AMICAR						
>A>	@ CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN	
>D>	@ XANODYNE PHARM	250MG/ML	N015229 002		Mar	CAHN	

SYRUP; ORAL

	AMICAR						
>A>	AA + CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN	
>D>	AA + XANODYNE PHARM	1.25GM/5ML	N015230 002		Mar	CAHN	

TABLET; ORAL

	AMICAR						
>A>	AB CLOVER PHARMS	500MG	N015197 001		Mar	CAHN	
>A>	+	1GM	N015197 002	Jun 24, 2004	Mar	CAHN	
>D>	AB XANODYNE PHARM	500MG	N015197 001		Mar	CAHN	
>D>	+	1GM	N015197 002	Jun 24, 2004	Mar	CAHN	

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@ TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Jan	DISC	
--	-------------------	---------	-------------	--------------	-----	------	--

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC	
	+	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD	
	LIMBITROL						
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC	
	LIMBITROL DS						
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC	

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA	
>A>	AB	EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA	

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVPAC

>A>	+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757 001	Dec 02, 1997	Mar	CAHN
-----	---	-------------------	--	-------------	--------------	-----	------

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

>D>	+	TAKEDA PHARMS NA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757 001	Dec 02, 1997	Mar	CAHN
-----	---	------------------	--	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
>D>	ANAGRELIDE HYDROCHLORIDE					
>D>	AB	SANDOZ	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar DISC
>D>	AB		EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar DISC
>A>	@	SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar DISC
>A>	@		EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar DISC

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan CTNA
		ARGATROBAN				
AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan NEWA
		MOVIPREP				
AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan CFTG

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb CAHN
----	--	-------------	-------------	-------------	--------------	----------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb CAHN
----	--	-------------	------------------	-------------	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb CTEC
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb NEWA
		ATRACURIUM BESYLATE PRESERVATIVE FREE				
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb CTEC
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb NEWA

AXITINIB

TABLET; ORAL

INLYTA

	PFIZER	1MG	N202324 001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

	@ UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
	@	20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GLAZO

+	SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

>A> AEROSOL, METERED; NASAL

>A> QNASL

>A>	+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA
-----	---	--------------------	-------------------	-------------	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984	Jan	CAHN
----	---	--------------	-------	-------------	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN
----	---	------------------	--------	-------------	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

	@ LANNETT HOLDINGS INC	0.5MG	A088877 001	Apr 11, 1985	Jan	DISC	
	@	1MG	A088894 001	Apr 11, 1985	Jan	DISC	
	@	2MG	A088895 001	Apr 11, 1985	Jan	DISC	
AA	PROSAM LABS	0.5MG	A040699 001	Feb 14, 2008	Feb	CMFD	
AA		1MG	A040705 001	Feb 14, 2008	Feb	CMFD	
AA		2MG	A040706 001	Feb 14, 2008	Feb	CMFD	
AA	+	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103 002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103 003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE DIPROPIONATE

	CREAM; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
	CREAM, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
	GEL, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN
	LOTION, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN
	OINTMENT, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

	CREAM; TOPICAL							
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
	LOTION; TOPICAL							
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
	LOTRISONE							
AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN

BETAMETHASONE VALERATE

	AEROSOL, FOAM; TOPICAL							
	LUXIQ							
	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

	TABLET; ORAL							
	ZEBETA							
AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BOCEPREVIR

	CAPSULE; ORAL							
	VICTRELIS							
>A>	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN
>D>	+	SCHERING	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

	INJECTABLE; INTRAVENOUS, SUBCUTANEOUS							
	VELCADE							
	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

	AEROSOL, METERED; INHALATION							
	SYMBICORT							
	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
	+		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
FORFIVO XL

>A>	+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
>D>	+	INTELGENX CORP	450MG	N022497 001	Nov 10, 2011	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB	APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
>A>		@	5MG	A075521 001	Apr 05, 2002	Mar	DISC
>D>	AB		10MG	A075521 002	Apr 05, 2002	Mar	DISC
>A>		@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
>D>	AB		15MG	A075521 003	Apr 05, 2002	Mar	DISC
>A>		@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
>D>	AB	EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
>A>		@	5MG	A075119 001	Mar 14, 2002	Mar	DISC
>D>	AB		10MG	A075119 002	Mar 14, 2002	Mar	DISC
>A>		@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
>D>	AB		15MG	A075119 003	Jan 23, 2003	Mar	DISC
>A>		@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
>D>	AB	PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
>A>		@	5MG	A075388 001	May 09, 2002	Mar	DISC
	AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
>D>	AB		10MG	A075388 002	May 09, 2002	Mar	DISC
>A>		@	10MG	A075388 002	May 09, 2002	Mar	DISC
	AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
>D>	AB		15MG	A075388 003	May 09, 2002	Mar	DISC
>A>		@	15MG	A075388 003	May 09, 2002	Mar	DISC
	AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
	AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAF CIT

AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAF CIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	---	--------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB		UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB			25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+		25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>A>	AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
>A>	AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
>A>	AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
>D>	AP	WATSON LABS	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
>D>	AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
>D>	AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN

PARAPLATIN

@ CORDEN PHARMA

@

@

50MG/VIAL
150MG/VIAL
450MG/VIAL

N019880 001 Mar 03, 1989 Feb CAHN
N019880 002 Mar 03, 1989 Feb CAHN
N019880 003 Mar 03, 1989 Feb CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
>A>	AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
>A>	AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
>A>	AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
>A>	AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN
>D>	AP	WATSON LABS	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
>D>	AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
>D>	AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
>D>	AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	--	-------------	-------	-------------	--------------	-----	------

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

AB	+	RANBAXY	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
AB	+		EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
AB	+		EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
AB	+		EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
AB			EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB			EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB			EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

>D>		CORNERSTONE THERAP	200MG	N021222 001	Aug 29, 2001	Mar	CAHN
>D>	+		400MG	N021222 002	Jul 21, 2008	Mar	CAHN
>A>		VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001	Mar	CAHN
>A>	+		400MG	N021222 002	Jul 21, 2008	Mar	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

>D>	AP	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
>A>	AP	+	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
>D>	AP		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA

TABLET; ORAL

CEFZIL

@ CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991 Feb CAHN

@

500MG

N050664 002 Dec 23, 1991 Feb CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION
CEFTRIAZONE

>D>	AP	SANDOZ	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
>D>	AP		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD
>A>	AP	+	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CICLESONIDE

AEROSOL, METERED; NASAL
ZETONNA

+ NYCOMED GMBH 0.037MG/INH

N202129 001 Jan 20, 2012 Jan NEWA

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA
----	-------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPROFLOXACIN

>D>	AP	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
>A>		@	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
		@	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE				
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
		NIMBEX				
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
		NIMBEX PRESERVATIVE FREE				
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

>D>	AP	TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC
>A>		@	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

>D>		LUNDBECK INC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
>D>			10MG	N202067 002	Oct 21, 2011	Mar	CAHN
>D>			20MG	N202067 003	Oct 21, 2011	Mar	CAHN
>A>		LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
>A>			10MG	N202067 002	Oct 21, 2011	Mar	CAHN
>A>			20MG	N202067 003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

>D>	AA	+	AZUR PHARMA	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN
>A>	AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209 001	Oct 04, 2005	Feb	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP		ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

>D>	AP	+	LUNDBECK INC	0.5MG/VIAL	N050682 001		Mar	CAHN
>A>	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

	+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Feb	CAHN
--	---	---------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

PREZISTA

		JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008	Feb	CAHN
			EQ 150MG BASE	N021976 005	Dec 18, 2008	Feb	CAHN
		@	EQ 300MG BASE	N021976 001	Jun 23, 2006	Feb	CAHN
			EQ 400MG BASE	N021976 003	Oct 21, 2008	Feb	CAHN
	+		EQ 600MG BASE	N021976 002	Feb 25, 2008	Feb	CAHN

DES Loratadine

TABLET; ORAL

DES Loratadine

AB		MYLAN PHARMS INC	5MG	A078351 001	Feb 10, 2012	Jan	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

Desmopressin Acetate

SOLUTION; NASAL

DDAVP

>D>		+	SANOFI AVENTIS US	0.01%	N017922 001		Mar	CFTG
>A>	AB	+		0.01%	N017922 001		Mar	CFTG
>A>			DESMOPRESSIN ACETATE					
>A>	AB		SUN PHARM INDS	0.01%	A077212 001	Apr 12, 2012	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

VIORELE

>A>	AB	GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346 001	Apr 02, 2012	Mar	NEWA
-----	----	-------------------	--------------------------	-------------	--------------	-----	------

DESONIDE

LOTION; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

>D>	AB	TARO	0.25%	A074286 001	Jun 07, 1996	Mar	CRLD
-----	----	------	-------	-------------	--------------	-----	------

>A>	AB	+	0.25%	A074286 001	Jun 07, 1996	Mar	CRLD
-----	----	---	-------	-------------	--------------	-----	------

>D>		TOPICORT					
-----	--	----------	--	--	--	--	--

>D>	AB	+	TARO PHARMS NORTH	0.25%	N018763 001	Sep 30, 1983	Mar	DISC
-----	----	---	-------------------	-------	-------------	--------------	-----	------

>A>		@	0.25%	N018763 001	Sep 30, 1983	Mar	DISC
-----	--	---	-------	-------------	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572 001	Apr 22, 2005	Feb	CRLD
----	---	----------------	----------------------	-------------	--------------	-----	------

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

AB1	+		0.05%	A075187 001	Mar 30, 1998	Jan	CAHN
-----	---	--	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845 001	Mar 08, 2012	Feb	NEWA
----	--	-------------------	-------	-------------	--------------	-----	------

AB	+	TEVA	500MG	A073673 001	Jul 31, 1992	Feb	CTEC
----	---	------	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC
--	--	-------------------	--------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

>D>								
>D>	AP	+	MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC

>A>		@	50MG/ML	N006146 002			Mar	DISC
-----	--	---	---------	-------------	--	--	-----	------

INJECTABLE; INJECTION

>D>		BENADRYL PRESERVATIVE FREE						
>D>	AP	+	MCNEIL CONS	50MG/ML	N009486	001		Mar DISC
>A>		@		50MG/ML	N009486	001		Mar DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

		@	TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997	Jan DISC
--	--	---	-----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

DIPYRIDAMOLE

AB			PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb CAHN
AB				50MG	A040542	002	Apr 21, 2006	Feb CAHN
AB				75MG	A040542	003	Apr 21, 2006	Feb CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB			DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012	Feb NEWA
AB			REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012	Feb NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP			ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jan CTEC
AP				80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jan CTEC
AP			APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	Jan NEWA
AP				80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	Jan NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

		+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Feb NEWA
--	--	---	-------------------	-------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

		@	NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000	Feb DISC
		@		EQ 2MG BASE	A075609	002	Oct 18, 2000	Feb DISC
		@		EQ 4MG BASE	A075609	003	Oct 18, 2000	Feb DISC
		@		EQ 8MG BASE	A075609	004	Oct 18, 2000	Feb DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

		+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994	Jan CAHN
--	--	---	----------------	----	---------	-----	--------------	----------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP			ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012	Jan NEWA
AP			SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012	Jan NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

		+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan CAHN
		+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>D>	AB	SANDOZ	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
>D>	AB		EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC
>A>		@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
>A>		@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

TABLET; ORAL

DOXYCYCLINE

>D>	AB	SANDOZ	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
>D>	AB		EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
>D>	AB		EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC
>A>		@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
>A>		@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
>A>		@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
AB		DOXYCYCLINE HYCLATE					
AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

		@ SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000	Feb	DISC
		@	2.5MG	A075496 001	Aug 22, 2000	Jan	DISC
		@	5MG	A075621 002	Aug 22, 2000	Feb	DISC
		@	5MG	A075496 002	Aug 22, 2000	Jan	DISC
		@	10MG	A075621 003	Aug 22, 2000	Feb	DISC
		@	10MG	A075459 001	Aug 22, 2000	Jan	DISC
		@	20MG	A075621 004	Aug 22, 2000	Feb	DISC
		@	20MG	A075459 002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	AB	SANDOZ	5MG;12.5MG	A076116 001	Sep 19, 2001	Mar	DISC
>D>	AB		10MG;25MG	A076116 002	Sep 19, 2001	Mar	DISC
>A>		@ SANDOZ INC	5MG;12.5MG	A076116 001	Sep 19, 2001	Mar	DISC
>A>		@	10MG;25MG	A076116 002	Sep 19, 2001	Mar	DISC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>A>	AT	LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
>D>	AT	PHARMAFORCE	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN

EPINEPHRINE

INJECTABLE; *****

ADRENACLICK

>A>	BX	+ COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
>A>	BX	+ TWINJECT 0.15	EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN
>A>	BX	+ COREPHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
>A>	BX	+ TWINJECT 0.3	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN

INJECTABLE; IM-SC

ADRENACLICK

>D>	BX	+ SHIONOGI INC	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
>D>	BX	+ TWINJECT 0.15	EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN
>D>	BX	+ SHIONOGI INC	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
>D>	BX	+ TWINJECT 0.3	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	AP	CIPLA LTD	50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
>A>	AP		200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
>A>	AP	HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
>A>	AP		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN
>A>	AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA
>A>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA
>D>	AP	WATSON LABS	200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
>D>	AP		50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
>D>	AP	X GEN PHARMS	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
>D>	AP		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	---------	-----	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
>A>	AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA

SOLUTION; ORALLEXAPRO

AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365 001	Nov 27, 2002	Feb	CFTG
----	---	-------------	-----------------	-------------	--------------	-----	------

TABLET; ORALESCITALOPRAM OXALATE

AB		IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765 001	Mar 14, 2012	Feb	NEWA
AB			EQ 10MG BASE	A076765 002	Mar 14, 2012	Feb	NEWA
AB			EQ 20MG BASE	A076765 003	Mar 14, 2012	Feb	NEWA

LEXAPRO

AB		FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb	CFTG
AB			EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb	CFTG
AB	+		EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb	CFTG

ESTRADIOL; NORETHINDRONE ACETATETABLET; ORALESTRADIOL AND NORETHINDRONE ACETATE

AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012	Feb	NEWA
----	--	-----------------	-------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL-28

>A>		FALMINA					
>A>	AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721 001	Mar 28, 2012	Mar	NEWA
		MARLISSA					
	AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452 001	Feb 29, 2012	Feb	NEWA

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28ALYACEN 1/35

AB		GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012	Jan	NEWA
----	--	-------------------	-------------	-------------	--------------	-----	------

ALYACEN 7/7/7

AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012	Jan	NEWA
----	--	-------------------	--	-------------	--------------	-----	------

>A>		WERA					
>A>	AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTIMATETABLET; ORAL-28NORGESTIMATE AND ETHINYL ESTRADIOL

>A>	AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
-----	----	-------------------	----------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTRELTABLET; ORAL-28ELINEST

>A>	AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
-----	----	-----------------	--------------	-------------	--------------	-----	------

ETODOLACTABLET; ORALETODOLAC

AB		PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
AB			500MG	A074819 002	Apr 28, 1998	Feb	CMFD

ETOPOSIDECAPSULE; ORALVEPESID@ CORDEN PHARMA@

		50MG	N019557 001	Dec 30, 1986	Feb	CAHN
		100MG	N019557 002	Dec 30, 1986	Feb	CAHN

INJECTABLE; INJECTIONETOPOSID

>D>	AP	APP PHARMS	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
>A>	AP	+ APP PHARMS LLC	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
>D>	AP	+ BEDFORD	20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
>A>	AP		20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
		VEPESID					
		@ CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983	Feb	CAHN

ETRAVIRINE

TABLET; ORAL

INTELENCE

>A>		JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012	Mar	NEWA
			100MG	N022187 001	Jan 18, 2008	Feb	CAHN
		+	200MG	N022187 002	Dec 22, 2010	Feb	CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

		+ AMYLIN	2MG/VIAL	N022200 001	Jan 27, 2012	Jan	NEWA
--	--	----------	----------	-------------	--------------	-----	------

EZETIMIBE

TABLET; ORAL

ZETIA

		+ MSD INTL GMBH	10MG	N021445 001	Oct 25, 2002	Feb	CAHN
		+ MSP SINGAPORE	10MG	N021445 001	Oct 25, 2002	Jan	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

		MSD INTL	10MG;10MG	N021687 001	Jul 23, 2004	Jan	CAHN
			10MG;20MG	N021687 002	Jul 23, 2004	Jan	CAHN
			10MG;40MG	N021687 003	Jul 23, 2004	Jan	CAHN
		+	10MG;80MG	N021687 004	Jul 23, 2004	Jan	CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB		MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB			250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB			500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

TABLET; ORAL

PEPCID

AB		MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB		+	40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

		@ UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
		@	40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB		LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
----	--	----------------	------	-------------	--------------	-----	------

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB	+	LUPIN ATLANTIS	130MG	N021695	003	Nov 30, 2004	Feb	CFTG
----	---	----------------	-------	---------	-----	--------------	-----	------

FENOFIBRATE (MICRONIZED)

AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

AB			130MG	A090859	002	Mar 01, 2012	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

>D>	AB		IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CRLD
-----	----	--	------------	-------	---------	-----	--------------	-----	------

>A>	AB	+		160MG	A076509	002	Mar 26, 2008	Mar	CRLD
-----	----	---	--	-------	---------	-----	--------------	-----	------

>D>	AB		TEVA	54MG	A076433	001	May 13, 2005	Mar	DISC
-----	----	--	------	------	---------	-----	--------------	-----	------

>A>			@	54MG	A076433	001	May 13, 2005	Mar	DISC
-----	--	--	---	------	---------	-----	--------------	-----	------

>D>	AB	+		160MG	A076433	002	May 13, 2005	Mar	DISC
-----	----	---	--	-------	---------	-----	--------------	-----	------

>A>			@	160MG	A076433	002	May 13, 2005	Mar	DISC
-----	--	--	---	-------	---------	-----	--------------	-----	------

>A>	AB		VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
-----	----	--	--------------	------	---------	-----	--------------	-----	------

>A>	AB			145MG	A090715	002	Apr 05, 2012	Mar	NEWA
-----	----	--	--	-------	---------	-----	--------------	-----	------

FENTANYL

SPRAY; SUBLINGUAL

SUBSYS

>D>			INSYS THERAP	0.1MCG	N202788	001	Jan 04, 2012	Mar	CPOT
-----	--	--	--------------	--------	---------	-----	--------------	-----	------

>A>				0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
-----	--	--	--	-------	---------	-----	--------------	-----	------

				0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
--	--	--	--	--------	---------	-----	--------------	-----	------

>D>				0.2MCG	N202788	002	Jan 04, 2012	Mar	CPOT
-----	--	--	--	--------	---------	-----	--------------	-----	------

>A>				0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
-----	--	--	--	-------	---------	-----	--------------	-----	------

				0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
--	--	--	--	--------	---------	-----	--------------	-----	------

>D>		+		0.4MCG	N202788	003	Jan 04, 2012	Mar	CPOT
-----	--	---	--	--------	---------	-----	--------------	-----	------

>A>		+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
-----	--	---	--	-------	---------	-----	--------------	-----	------

		+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
--	--	---	--	--------	---------	-----	--------------	-----	------

>D>				0.6MCG	N202788	004	Jan 04, 2012	Mar	CPOT
-----	--	--	--	--------	---------	-----	--------------	-----	------

>A>				0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
-----	--	--	--	-------	---------	-----	--------------	-----	------

				0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
--	--	--	--	--------	---------	-----	--------------	-----	------

>D>				0.8MCG	N202788	005	Jan 04, 2012	Mar	CPOT
-----	--	--	--	--------	---------	-----	--------------	-----	------

>A>				0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
-----	--	--	--	-------	---------	-----	--------------	-----	------

				0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA
--	--	--	--	--------	---------	-----	--------------	-----	------

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

		ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
--	--	------------	---------------	---------	-----	--------------	-----	------

	+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT
--	---	--	---------------	---------	-----	--------------	-----	------

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB		PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
----	--	-----------	---------------	---------	-----	--------------	-----	------

AB			EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

AB			EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

AB			EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

AB			EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

AB			EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
----	--	--------------------	----------------------	---------	-----	--------------	-----	------

AP			400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA
----	--	--	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

@	PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
@		100MG	A076424 002	Jul 29, 2004	Feb	DISC
@		150MG	A076424 003	Jul 29, 2004	Feb	DISC
@		200MG	A076424 004	Jul 29, 2004	Feb	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

>D>	FLUDARA					
>D>	AP	+ GENZYME	50MG/VIAL	N020038 001	Apr 18, 1991	Mar DISC
>A>		@ GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar DISC
		FLUDARABINE PHOSPHATE				
>D>	AP	HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar CRLD
>A>	AP	+	50MG/VIAL	A077790 001	Apr 06, 2007	Mar CRLD

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@	TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan	DISC
@		1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan	DISC

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001		Jan	CAHN
---	-------------	----	-------------	--	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

>D>	AB	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar CRLD
>A>	AB	+	125MG	A075780 001	Sep 19, 2001	Mar CRLD
>D>	AB	SANDOZ	125MG	A075818 001	Sep 18, 2001	Mar CRLD
>A>	AB	SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan CAHN
----	---	----------------	-------	-------------	--------------	----------

CREAM; TOPICAL

	FLUTICASON PROPIONATE								
AB	FOUGERA PHARMS	0.05%		A076451	001	May 14, 2004	Jan	CAHN	

OINTMENT; TOPICAL

	FLUTICASON PROPIONATE								
AB	FOUGERA PHARMS	0.005%		A076300	001	May 14, 2004	Jan	CAHN	

FLUVASTATIN SODIUM

CAPSULE; ORAL

>A>	FLUVASTATIN SODIUM								
>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012	Mar	NEWA	
>A>	AB		EQ 40MG BASE	A090595	002	Apr 11, 2012	Mar	NEWA	
	LESCOL								
>D>	NOVARTIS		EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG	
>A>	AB		EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG	
>D>	+		EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG	
>A>	AB	+	EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG	

FOSINOPRIL SODIUM

TABLET; ORAL

>D>	MONOPRIL								
>D>	AB	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Mar	DISC	
>A>	@		10MG	N019915	002	May 16, 1991	Mar	DISC	
>D>	AB		20MG	N019915	003	May 16, 1991	Mar	DISC	
>A>	@		20MG	N019915	003	May 16, 1991	Mar	DISC	
>D>	AB	+	40MG	N019915	004	Mar 28, 1995	Mar	DISC	
>A>	@		40MG	N019915	004	Mar 28, 1995	Mar	DISC	

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP	TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC	
>A>	@		EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC	

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

>A>	AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012	Mar	NEWA	
-----	----	---------------	-----------	---------	-----	--------------	-----	------	--

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	NEXGEN PHARMA	1.5MG		A091522	001	Mar 12, 2012	Feb	NEWA	
----	---------------	-------	--	---------	-----	--------------	-----	------	--

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN	
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN	
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN	
>D>	AP	WATSON LABS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN	
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN	
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN	

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

>D>		HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>		@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC
>A>		@	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC
>D>		HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC
>A>		@	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC
>D>		HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC
>A>		@	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC
>D>	AP		10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC
>A>		@	10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Jan	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

>D>	+	SANOFI AVENTIS	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG
>A>	AB	+	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG
>D>	+		12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG
>A>	AB	+	12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG
>A>		+	12.5MG;300MG	N020758	003	Aug 31, 1998	Feb	CRLD
>A>		IRBESARTAN AND HYDROCHLOROTHIAZIDE						
>A>	AB	TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012	Mar	NEWA
>A>	AB		12.5MG;300MG	A077369	002	Mar 30, 2012	Mar	NEWA
>A>			25MG;300MG	A077369	003	Mar 30, 2012	Mar	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;50MG	A091617	001	Feb 17, 2012	Feb	NEWA
AB			12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA
AB			25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
	12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
@		12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
@		25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT	+ FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
----	------------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+ FOUGERA PHARMS	1%	A080692 001		Jan	CAHN
----	------------------	----	-------------	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT	FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN
----	----------------	--------	-------------	--	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

>D>	AB	TARO	0.2%	A075042 001	Aug 25, 1998	Mar	CRLD
>A>	AB	+	0.2%	A075042 001	Aug 25, 1998	Mar	CRLD
>D>		WESTCORT					
>D>	AB	+ RANBAXY	0.2%	N017950 001		Mar	DISC
>A>		@	0.2%	N017950 001		Mar	DISC

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+ SHIRE LLC	50MG	N011949 001		Jan	CAHN
----	-------------	------	-------------	--	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@	STI PHARMA LLC	10MG/5ML	A086880 001			Feb	CAHN
---	----------------	----------	-------------	--	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

>A>	AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
>D>		+	ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
>A>			IBANDRONATE SODIUM					
>A>	AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
>A>	AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
>A>	AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
>A>	AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

>D>		+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
>A>		+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>D>		+	TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
>A>		@		5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
>D>		+		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
>A>		@		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
>D>		+		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC
>A>		@		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB			PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB				25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB				50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

>A>	AB		APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
	AB		FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
	AB		GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

>D>	AP	+	LUNDBECK INC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
>A>	AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

	LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

IRBESARTAN

TABLET; ORAL

AVAPRO

>D>		SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
>A>	AB		75MG	N020757 001	Sep 30, 1997	Mar	CFTG
>D>			150MG	N020757 002	Sep 30, 1997	Mar	CFTG
>A>	AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
>D>		+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG
>A>	AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG
>A>		IRBESARTAN					
>A>	AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
>A>	AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
>A>	AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
>A>	AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
	AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
	AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
>A>	AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
>A>	AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
>D>	AP	TEVA PARENTERAL	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC
>A>		@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC
>D>	AP	WATSON LABS	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
>D>	AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
>D>	AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
>D>	AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

@	SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC
---	---------------	------	-------------	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL

MYORISAN

AB		DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB			20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB			40MG	A076485 003	Jan 19, 2012	Jan	NEWA

IVACAFTOR

TABLET; ORAL

KALYDECO

+	VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	-------------	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL
SKLICE

+ SANOFI PASTEUR 0.5% N202736 001 Feb 07, 2012 Feb NEWA

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

AB FOUGERA PHARMS 2% A076294 001 Apr 28, 2004 Jan CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

>A> AP GLAND PHARMA LTD 5MG/ML A090699 001 Apr 03, 2012 Mar NEWA

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA FRESENIUS KABI 10GM/15ML A090503 001 Jan 25, 2012 Jan NEWA

SOLUTION; ORAL, RECTAL
LACTULOSE

AA FRESENIUS KABI 10GM/15ML A090502 001 Jan 25, 2012 Jan NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

>D> AB TAKEDA PHARMS NA 15MG N020406 001 May 10, 1995 Mar CAHN

>D> AB + 30MG N020406 002 May 10, 1995 Mar CAHN

>A> AB TAKEDA PHARMS USA 15MG N020406 001 May 10, 1995 Mar CAHN

>A> AB + 30MG N020406 002 May 10, 1995 Mar CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

>D> LANSOPRAZOLE

>D> AB TEVA PHARMS 15MG A078730 001 Oct 15, 2010 Mar DISC

>A> @ 15MG A078730 001 Oct 15, 2010 Mar DISC

>D> AB 30MG A078730 002 Oct 15, 2010 Mar DISC

>A> @ 30MG A078730 002 Oct 15, 2010 Mar DISC

PREVACID

>D> AB TAKEDA PHARMS NA 15MG N021428 001 Aug 30, 2002 Mar CTEC

>D> AB + 30MG N021428 002 Aug 30, 2002 Mar CTEC

>A> TAKEDA PHARMS USA 15MG N021428 001 Aug 30, 2002 Mar CTEC

>A> + 30MG N021428 002 Aug 30, 2002 Mar CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL

@ SHIRE LLC EQ 250MG BASE N021468 001 Oct 26, 2004 Feb CAHN

EQ 500MG BASE N021468 002 Oct 26, 2004 Feb CAHN

EQ 750MG BASE N021468 003 Nov 23, 2005 Feb CAHN

+ EQ 1GM BASE N021468 004 Nov 23, 2005 Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

>D> AP TEVA PARENTERAL EQ 50MG BASE/VIAL A081278 001 Sep 28, 1993 Mar DISC

>A> @ EQ 50MG BASE/VIAL A081278 001 Sep 28, 1993 Mar DISC

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA
	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA
		SOLUTION; ORAL					
		LEVETIRACETAM					
	AA	HI-TECH PHARMACAL	100MG/ML	A090601 001	Feb 28, 2012	Feb	NEWA
>A>	AA	VINTAGE PHARMS	100MG/ML	A090079 001	Apr 11, 2012	Mar	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

>A>	AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
>A>	AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
>A>	AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
>A>	AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
>A>	AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
>A>	AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
	AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
	AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
	AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB		FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan	CAHN
----	--	----------------	-----------	-------------	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

		BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
			2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
		+	2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012	Jan	NEWA
----	--	-------------------	--------	-------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

		HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
			40GM/1000ML(40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT		MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
----	--	------------------	------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
-----	----	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	EPIC PHARMA LLC	25MG	A200294 002	Apr 13, 2012	Mar	NEWA
-----	----	-----------------	------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
-----	----	-----------------	-----	-------------	--------------	-----	------

>A>		@	5MG	A090044 001	Mar 12, 2012	Mar	DISC
-----	--	---	-----	-------------	--------------	-----	------

	AB		5MG	A090044 001	Mar 12, 2012	Feb	NEWA
--	----	--	-----	-------------	--------------	-----	------

>D>	AB		10MG	A090044 002	Mar 12, 2012	Mar	DISC
-----	----	--	------	-------------	--------------	-----	------

>A>		@	10MG	A090044 002	Mar 12, 2012	Mar	DISC
-----	--	---	------	-------------	--------------	-----	------

	AB		10MG	A090044 002	Mar 12, 2012	Feb	NEWA
--	----	--	------	-------------	--------------	-----	------

NAMENDA

>D>	AB	FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CTEC
-----	----	-------------	-----	-------------	--------------	-----	------

>A>			5MG	N021487 001	Oct 16, 2003	Mar	CTEC
-----	--	--	-----	-------------	--------------	-----	------

	AB		5MG	N021487 001	Oct 16, 2003	Feb	CTEC
--	----	--	-----	-------------	--------------	-----	------

>D>	AB	+	10MG	N021487 002	Oct 16, 2003	Mar	CTEC
-----	----	---	------	-------------	--------------	-----	------

>A>		+	10MG	N021487 002	Oct 16, 2003	Mar	CTEC
-----	--	---	------	-------------	--------------	-----	------

	AB	+	10MG	N021487 002	Oct 16, 2003	Feb	CTEC
--	----	---	------	-------------	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

ROWASA

		@ MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
--	--	---------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP		MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	--	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
----	--	-----------------	-------	-------------	--------------	-----	------

AB			850MG	A090888 002	Mar 12, 2012	Feb	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			1GM	A090888 003	Mar 12, 2012	Feb	NEWA
----	--	--	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1		INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
-----	--	-------------------	-------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
--	--	-------------------	--------------------	-------------	--------------	-----	------

			1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
--	--	--	------------------	-------------	--------------	-----	------

	+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA
--	---	--	-------------------	-------------	--------------	-----	------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
----	--	-------------	-----	-------------	--------------	-----	------

AB			10MG	A202068 002	Mar 07, 2012	Feb	NEWA
----	--	--	------	-------------	--------------	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>		@ SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
>A>	AA		500MG	A086989 001		Mar	CMFD
>D>		@	750MG	A086988 001		Mar	CMFD
>A>	AA		750MG	A086988 001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP		APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	---	---------	--	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
>A>	AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
>A>	AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
>A>	AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYLOTHIAZIDE

TABLET; ORAL

ENDURON

>D>		ABBOTT	2.5MG	N012524 001		Mar	DISC
>D>	AB	+	5MG	N012524 004		Mar	DISC
>A>		@ ABBOTT LABS PHARM	2.5MG	N012524 001		Mar	DISC
>A>		@	5MG	N012524 004		Mar	DISC

METHYLOTHIAZIDE

>D>	AB		MYLAN	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
>A>	AB	+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

>D>	AP		TEVA PARENTERAL	50MG/ML	A072974 001	Nov 22, 1991	Mar	DISC
>A>		@		50MG/ML	A072974 001	Nov 22, 1991	Mar	DISC

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB			10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB			20MG	A090710 003	Mar 15, 2012	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>D>	AP	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC
>A>		@	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

		@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
--	--	-------------------	----------------	-------------	--------------	-----	------

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP			EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB		SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+		5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB			10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

	+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
--	---	----------------	-------	-------------	--------------	-----	------

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

	+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
--	---	---------------	------------	-------------	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

+	APTALIS PHARMA	0.4%	N021359 001	Jun 21, 2011	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

>D>	AB	SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988	Mar	DISC
-----	----	--------------------	-------	-------------	--------------	-----	------

>A>	@		150MG	N019508 001	Apr 12, 1988	Mar	DISC
-----	---	--	-------	-------------	--------------	-----	------

>D>	AB	+	300MG	N019508 002	Apr 12, 1988	Mar	DISC
-----	----	---	-------	-------------	--------------	-----	------

>A>	@		300MG	N019508 002	Apr 12, 1988	Mar	DISC
-----	---	--	-------	-------------	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>A>	AP	SINETICA	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	Mar	NEWA
-----	----	----------	----------------	-------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
----	----------------	------------------	-------------	--	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan	CAHN
----	---	----------------	------------------	-------------	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

>D>	AP	INNOPHARMA LLC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN
-----	----	----------------	-----------	-------------	--------------	-----	------

>A>	AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
-----	----	-------------	-----------	-------------	--------------	-----	------

>A>	AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN
-----	----	------------	-----------	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

>A>	AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>D>	AP	TEVA PARENTERAL	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
>D>	AP		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD
>A>	AP	+ TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
>A>	AP	+	100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN
---	-----------------	----	-------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET; ORAL

>D>		DITROPAN					
>D>	AB	+ JANSSEN PHARMS	5MG	N017577 001		Mar	DISC
>A>		@	5MG	N017577 001		Mar	DISC
		OXYBUTYNIN CHLORIDE					
>D>	AB	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
>A>	AB	+	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
		TABLET, EXTENDED RELEASE; ORAL					
		OXYBUTYNIN CHLORIDE					
>A>	AB	MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

	+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
--	---	------------	---------	-------------	--------------	-----	------

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

		@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
>D>	AP		100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC
>A>		@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

>D>		@ BRISTOL MYERS SQUIBB	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN
>A>		@ CORDEN PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

>D>							
>D>	AP	+	NOVARTIS	30MG/VIAL	N020036 001	Oct 31, 1991	Mar DISC
>A>		@		30MG/VIAL	N020036 001	Oct 31, 1991	Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

		ABBOTT LABS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Feb	CAHN
			60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Feb	CAHN
		+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Feb	CAHN
>A>		ULTRESA					
>A>		APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012	Mar	NEWA
>A>			41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222 002	Mar 01, 2012	Mar	NEWA
>A>		+	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA
>A>		TABLET; ORAL					
>A>		VIOKACE					
>A>		APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
>A>		+	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB			EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
----	--	-------------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

>A> PEGINESATIDE ACETATE

>A> SOLUTION; INTRAVENOUS, SUBCUTANEOUS

>A> OMONTYS

>A>	+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

>A> OMONTYS PRESERVATIVE FREE

>A>	+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
----	---------	------	-------------	--------------	-----	------

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@	SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC
---	------------	------	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

>A>	CITIUS PHARMS	37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA
-----	---------------	--------	-------------	--------------	-----	------

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

>D>		TAKEDA PHARMS NA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
>D>			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
>D>		+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN
>A>		TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
>A>			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
>A>		+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

>D>		K+10					
>D>	BC	FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
>A>		@	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
>D>		KAON CL-10					
>D>	BC	SAVAGE LABS	10MEQ	N017046 002		Mar	DISC
>A>		@	10MEQ	N017046 002		Mar	DISC
>D>		KLOR-CON M20					
>D>	AB	UPSHER SMITH	20MEQ	A074726 001	Nov 20, 1998	Mar	CRLD
>A>	AB	+	UPSHER-SMITH LABS	A074726 001	Nov 20, 1998	Mar	CRLD
>D>		KLOTRIX					
>D>	BC	APOTHECON	10MEQ	N017850 001		Mar	DISC
>A>		@	10MEQ	N017850 001		Mar	DISC
>D>		POTASSIUM CHLORIDE					
>D>	AB	NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
>A>		@	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
>D>	AB	SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
>A>		@	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
>D>	AB	+	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC
>A>		@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

		@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN
		@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb	CAHN

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

PREGABALIN

CAPSULE; ORAL

LYRICA

PF PRISM

		25MG	N021446 001	Dec 30, 2004	Jan	CAHN
		50MG	N021446 002	Dec 30, 2004	Jan	CAHN
		75MG	N021446 003	Dec 30, 2004	Jan	CAHN
		100MG	N021446 004	Dec 30, 2004	Jan	CAHN
		150MG	N021446 005	Dec 30, 2004	Jan	CAHN
		200MG	N021446 006	Dec 30, 2004	Jan	CAHN

CAPSULE; ORAL

LYRICA

	PF PRISM	225MG	N021446 007	Dec 30, 2004	Jan	CAHN
+		300MG	N021446 008	Dec 30, 2004	Jan	CAHN

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	-------------	--------------	-----	------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA
AB		200MG	A202121 002	Feb 29, 2012	Feb	NEWA

PROMETRIUM

AB	ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG
AB	+	200MG	N019781 002	Oct 15, 1999	Feb	CFTG

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

>A>						
>A>	AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar NEWA
>A>	AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar NEWA
>A>	AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar NEWA
>A>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar NEWA
>A>	AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar NEWA
>A>	AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar NEWA

TABLET; ORAL

>A> QUETIAPINE FUMARATE

>A>	AB	ROXANE	EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
>A>	AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
>A>	AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA

SEROQUEL

>D>	+	ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
>A>	AB	+	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
>D>			EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
>A>	AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
>D>			EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
>A>	AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
>D>			EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
>A>	AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
>D>	+		EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
>A>	AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
>D>			EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG
>A>	AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

TABLET; ORAL

ALTACE

@ KING PFIZER

@

@

@

@

1.25MG

2.5MG

5MG

10MG

N022021 001 Feb 27, 2007 Jan DISC

N022021 002 Feb 27, 2007 Jan DISC

N022021 003 Feb 27, 2007 Jan DISC

N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

>A>	AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
>D>	AP	+	GLAXOSMITHKLINE	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
			ZANTAC IN PLASTIC CONTAINER					
>A>	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN	
>A>	@		EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN	
>D>	+	GLAXOSMITHKLINE	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN	
>D>	@		EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN	

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB	PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD

TABLET; ORAL

	SIMVASTATIN							
AB	PROSAM LABS	80MG		A078735	005	Aug 30, 2010	Feb	CMFD

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	@ MALLINCKRODT INC	460MG/GM;420MG/GM		N018509	001	Aug 07, 1985	Jan	CAHN
--	--------------------	-------------------	--	---------	-----	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML		A201850	001	Jan 20, 2012	Jan	NEWA
----	---------------	--------	--	---------	-----	--------------	-----	------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MEDEFIL	9MG/ML		N202832	001	Jan 06, 2012	Jan	NEWA
--	---------	--------	--	---------	-----	--------------	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

	JUBILANT DRAXIMAGE	9-100mCi		N021305	006	May 19, 2005	Feb	CAHN
--	--------------------	----------	--	---------	-----	--------------	-----	------

	@	2-200mCi		N021305	004	Nov 18, 2004	Jan	DISC
--	---	----------	--	---------	-----	--------------	-----	------

SOLUTION; ORAL

HICON

	@ JUBILANT DRAXIMAGE	1-500mCi/0.5ML		N021305	003	Jan 24, 2003	Feb	DISC
--	----------------------	----------------	--	---------	-----	--------------	-----	------

	@	1-250mCi/0.25ML		N021305	002	Jan 24, 2003	Feb	DISC
--	---	-----------------	--	---------	-----	--------------	-----	------

	@	1-1000mCi/ML		N021305	005	Apr 04, 2006	Feb	DISC
--	---	--------------	--	---------	-----	--------------	-----	------

+		250-1000mCi		N021305	007	Dec 05, 2011	Jan	NEWA
---	--	-------------	--	---------	-----	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)		N203922	001	Feb 14, 2012	Feb	NEWA
---	-------------	----------------------	--	---------	-----	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)		N203923	001	Feb 14, 2012	Feb	NEWA
---	-------------	------------------------	--	---------	-----	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

>D>	+	LUNDBECK INC	100MG	N019998	002	Jan 30, 1991	Mar	CAHN
-----	---	--------------	-------	---------	-----	--------------	-----	------

>A>	+	LUNDBECK LLC	100MG	N019998	002	Jan 30, 1991	Mar	CAHN
-----	---	--------------	-------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%		A077015	001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	--	---------	-----	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

>D>	+	AZUR PHARMA	15%	N006530	003	Jan 27, 1987	Mar	CAHN
-----	---	-------------	-----	---------	-----	--------------	-----	------

>A>	+	JAZZ PHARMS COMMERCL	15%	N006530	003	Jan 27, 1987	Mar	CAHN
-----	---	----------------------	-----	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

AVC

>D>	@ AZUR PHARMA	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
>A>	@ JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D>	AP	BEDFORD LABS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
>A>	AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	-------------	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PARENTERAL	1MG/ML	A076853 001	Jul 20, 2004	Jan	DISC
---	-----------------	--------	-------------	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT
			1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb	CPOT
----	---	-----------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE

		TEVA PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763 002	Feb 14, 2012	Feb	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO		MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN
----	--	---------------------	----------	-------------	--------------	-----	------

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

AO		MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN
----	--	---------------------	----------	-------------	--------------	-----	------

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002	Jan	CAHN
		0.1%	A086576 001	Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003	Jan	CAHN
---	----------------	------	-------------	-----	------

THEOPHYLLINE

INJECTABLE; INJECTION

>D> THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+	BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
>A>			@	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
>D>	AP	+		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
>A>			@	40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
>D>	AP	+		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
>A>			@	80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
>D>	AP	+		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
>A>			@	160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
>D>	AP	+		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
>A>			@	200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
>D>	AP	+		320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
>A>			@	320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
>D>	AP	+		400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC
>A>			@	400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@ CEPHALON

@

@

6MG
8MG
10MG

N020646 006	Nov 29, 2005	Jan	DISC
N020646 007	Nov 29, 2005	Jan	DISC
N020646 008	Nov 29, 2005	Jan	DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
	ZANAFLEX					
AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

>D>	AB	MYLAN	500MG	A086445 001	Mar	CRLD
>A>	+	MYLAN PHARMS INC	500MG	A086445 001	Mar	CRLD

TABLET; ORALTOLBUTAMIDE

>D>	AB	WATSON LABS	500MG	A087318 001		Mar	DISC
>D>	AB	+	500MG	A086109 001		Mar	DISC
>A>		@	500MG	A087318 001		Mar	DISC
>A>		@	500MG	A086109 001		Mar	DISC

TRAMADOL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORAL

>A>		RYBIX ODT					
>A>	+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
>D>		TRAMADOL HYDROCHLORIDE					
>D>	+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA

TRANEXAMIC ACIDINJECTABLE; INJECTIONTRANEXAMIC ACID

AP		NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA
----	--	--------------	----------	-------------	--------------	-----	------

TRANLYCYPROMINE SULFATETABLET; ORALPARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRETINOINCREAM; TOPICALRENOVA

	+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jan	CAHN
		RETIN-A					
AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522 001		Jan	CAHN
AB	+		0.1%	N017340 001		Jan	CAHN

GEL; TOPICALRETIN-A

AB	+	VALEANT INTL	0.01%	N017955 001		Jan	CAHN
AB	+		0.025%	N017579 002		Jan	CAHN

SOLUTION; TOPICALRETIN-A

AT	+	VALEANT INTL	0.05%	N016921 001		Jan	CAHN
----	---	--------------	-------	-------------	--	-----	------

SWAB; TOPICALRETIN-A

@ VALEANT INTL

			0.05%	N016921 002		Jan	CAHN
--	--	--	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDECREAM; TOPICALTRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
AT			0.1%	A085692 003		Jan	CAHN
AT	+		0.5%	A085692 002		Jan	CAHN

LOTION; TOPICALTRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
AT			0.1%	A040467 002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691 001	Jan	CAHN
AT		0.1%	A085691 003	Jan	CAHN
AT		0.5%	A085691 002	Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

>D>	AB	TEVA BRANDED PHARM	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN
>A>	AB	TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

>A>	AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar	NEWA
>A>	AB		EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

>D>		VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
>A>	AB		EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
>D>		+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG
>A>	AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG
>A>		VANCOMYCIN HYDROCHLORIDE					
>A>	AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
>A>	AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
>A>	AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

		IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
		+	300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
>A>	AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
>A>	AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

		+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
--	--	---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

>A>	AB	TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
>A>	AB		200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

>D>		@ AZUR PHARMA II	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
>A>		@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

>D>	+	AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
>D>	+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN
>D>	+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
>A>	+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
>A>	+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
>A>	+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

>A>	+	MCNEIL CONS	800MG;10MG;165MG	N020958 001	Oct 16, 2000	Mar	CAHN
>D>	+	MERCK SHARP DOHME	800MG;10MG;165MG	N020958 001	Oct 16, 2000	Mar	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

>D>	+	3M INFECTION	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWAB

>D>	+	3M INFECTION	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWABSTICK

>D>	+	3M INFECTION	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012 Feb NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

>A>	@	MCNEIL CONS	10MG	N020801 001	Sep 24, 1998	Mar	CAHN
>A>	+		20MG	N020801 002	Dec 17, 2007	Mar	CAHN
>D>	@	MERCK SHARP DOHME	10MG	N020801 001	Sep 24, 1998	Mar	CAHN
>D>	+		20MG	N020801 002	Dec 17, 2007	Mar	CAHN

TABLET; ORAL

PEPCID AC

>A>		MCNEIL CONS	10MG	N020325 001	Apr 28, 1995	Mar	CAHN
>A>	+		20MG	N020325 002	Sep 23, 2003	Mar	CAHN
>D>		MERCK SHARP DOHME	10MG	N020325 001	Apr 28, 1995	Mar	CAHN
>D>	+		20MG	N020325 002	Sep 23, 2003	Mar	CAHN

PEPCID AC (GELTAB)

>A>		MCNEIL CONS	10MG	N020902 001	Aug 05, 1999	Mar	CAHN
>D>		MERCK SHARP DOHME	10MG	N020902 001	Aug 05, 1999	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

		SUN PHARM INDS	30MG	A091567 002	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	30MG	A079112 002	Feb 08, 2012	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

		SUN PHARM INDS	30MG	A091567 001	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	30MG	A079112 001	Feb 08, 2012	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

		SUN PHARM INDS	60MG	A091567 004	Feb 06, 2012	Jan	NEWA
			180MG	A091567 006	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	60MG	A079112 004	Feb 08, 2012	Jan	NEWA

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

WOCKHARDT LTD	180MG	A079112 006	Feb 08, 2012	Jan	NEWA
---------------	-------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567 003	Feb 06, 2012	Jan	NEWA
----------------	------	-------------	--------------	-----	------

	180MG	A091567 005	Feb 06, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

WOCKHARDT LTD	60MG	A079112 003	Feb 08, 2012	Jan	NEWA
---------------	------	-------------	--------------	-----	------

	180MG	A079112 005	Feb 08, 2012	Jan	NEWA
--	-------	-------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338 001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA
--------------	--------------	-------------	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2012

NO MARCH 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	>A> 8148356	May 21, 2026	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	>A> 8129362	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	>A> 8132712	Sep 07, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	>A> 6589508	Apr 03, 2013	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	>A> 5605674	Feb 25, 2014	DP		>A> NP	Mar 23, 2015
	>A> 5683677	Nov 04, 2014	DP			
	>A> 5776432	Jul 07, 2015	DP			
	>A> 7780038	Jan 24, 2027	DP			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	>A> 5196404	Dec 15, 2014	DS DP U-1232			
	>A> 5196404	Dec 15, 2014	DS DP U-1040			
	>A> 5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	>A> 8119602	Mar 17, 2027	U-1233			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	>A> 8133890	Apr 19, 2022	U-1235			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	>A> 5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	>A> 5856346	Jan 05, 2021	DS DP U-893			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028				U-1161
	8097655	Oct 06, 2028				U-1020
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016				U-935
	6037157	Jun 26, 2016				U-1209
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016				U-935
	6703403	Jun 26, 2016				U-1209
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019				U-935
	7470506	Jun 23, 2019				U-1209
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016				U-935
	6037157	Jun 26, 2016				U-1209
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016				U-935
	6703403	Jun 26, 2016				U-1209
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019				U-935
	7470506	Jun 23, 2019				U-1209
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	>A> 5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	>A> 5925730	May 18, 2021	DS DP U-943			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001					>A> I-648	Mar 14, 2015
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DROSPIRENONE; ETHINYL ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765	001				>A> PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765	002				>A> PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765	003				>A> PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957	001	5877192	May 27, 2014	U-773		
		5877192	May 27, 2014	U-729		
		5877192	May 27, 2014	U-1207		
		5877192*PED	Nov 27, 2014			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957	002	5877192	May 27, 2014	U-773		
		5877192	May 27, 2014	U-729		
		5877192	May 27, 2014	U-1207		
		5877192*PED	Nov 27, 2014			
<u>ETRAVIRINE - INTELENCE</u>						
N022187	001				>A> NPP	Mar 26, 2015
<u>ETRAVIRINE - INTELENCE</u>						
N022187	002				>A> NPP	Mar 26, 2015
<u>ETRAVIRINE - INTELENCE</u>						
N022187	003				>A> NPP >A> NCE	Mar 26, 2015 Jan 18, 2013
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200	001	5424286	Dec 01, 2016	U-1108	NP	Jan 27, 2015
		6479065	Aug 10, 2020	DP		
		6495164	May 25, 2020	DP		
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6858576	Jan 06, 2017	U-656		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP U-1223		
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP U-1223		
		7741269	Jan 07, 2018	U-1224		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	001				>A> M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	002				>A> M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445	001				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	001				M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	002				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	003				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	001	>A> 8124125	Oct 01, 2024	DP U-1234		
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	002	>A> 8124125	Oct 01, 2024	DP U-1234		
<u>FENTANYL - SUBSYS</u>						
N202788	001				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	002				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	003				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	004				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	005				NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001	8092832	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	002	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	003	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	004	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	005	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030	001	8088398	Jun 07, 2027	DP U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030	002	8088398	Jun 07, 2027	DP U-913		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	>A> 6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8114909	Apr 11, 2026	U-1231			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	>A> 6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	>A> 6676929	May 04, 2020	DP			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	>A> 5310912	Feb 25, 2013	DS			
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023				U-1216
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023				U-1216
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023				U-1216

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	>A> 8119648	Aug 12, 2023	U-774			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	>A> 7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					>A> NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					>A> NPP	Mar 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830	002				>A> NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409	001				>A> NPP	Mar 26, 2015
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599	002				NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165	004	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	005	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	006	8075911	May 22, 2021	DP		
<u>NITRIC OXIDE - INOMAX</u>						
N020845	002	5558083	Nov 22, 2013	DP U-1226		
		5558083*PED	May 22, 2014			
		5732693	Dec 13, 2016	DP U-1230		
		5732693*PED	Jun 13, 2017			
		5752504	Dec 13, 2016	DP U-1230		
		5752504*PED	Jun 13, 2017			
<u>NITRIC OXIDE - INOMAX</u>						
N020845	003	5558083	Nov 22, 2013	DP U-1226		
		5558083*PED	May 22, 2014			
		5732693	Dec 13, 2016	DP U-1230		
		5732693*PED	Jun 13, 2017			
		5752504	Dec 13, 2016	DP U-1230		
		5752504*PED	Jun 13, 2017			
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705	002	>A> 7872049	Mar 14, 2028	DP U-39		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285	001	8119148	Dec 19, 2020	DP U-724		
		8119148*PED	Jun 19, 2021			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272	001	8114383	Oct 10, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272	002	8114383	Oct 10, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272	003	8114383	Oct 10, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272	004	8114383	Oct 10, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272	005	8114383	Oct 10, 2024	DP		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655	001	>A> 7851482	Jul 10, 2029	DS		
		8114383	Aug 08, 2024	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	>A> 7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	>A> 8138229	Dec 09, 2023	DP U-1092			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					>A> NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					>A> NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					>A> NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					>A> NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					>A> NCE	Mar 01, 2017
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001					>A> NCE	Mar 27, 2017
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002					>A> NCE	Mar 27, 2017
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003					>A> NCE	Mar 27, 2017
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004					>A> NCE	Mar 27, 2017
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005					>A> NCE	Mar 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799	006				>A> NCE	Mar 27, 2017
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684	001	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684	002	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684	003	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684	004	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750	001	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750	002	>A> 8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750	003	>A> 8133883	Apr 14, 2023	DP U-282		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145	001				>A> M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045	001	7169780	Oct 03, 2023	DS DP	>A> M-114	Mar 28, 2015
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7754731	Mar 11, 2029	DS DP U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045	002	7169780	Oct 03, 2023	DS DP	>A> M-114	Mar 28, 2015
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7754731	Mar 11, 2029	DS DP U-257		
<u>REGADENOSON - LEXISCAN</u>						
N022161	001	8106029	Jun 22, 2019	U-1042		
		8106183	Feb 02, 2027	DS		
		>A> 8133879	Jun 22, 2019	DP		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022	001	8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
<u>ROTIGOTINE - NEUPRO</u>						
N021829	001				>A> I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829	002				>A> I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829	003				>A> I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8118771	Aug 10, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		NCE	May 30, 2012
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
					PED	Nov 30, 2012
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-250		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-248			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DP U-999	Y		
	5935946	Jul 25, 2017	DP U-248	Y		
	5935946	Jul 25, 2017	DP U-250	Y		
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					>A> NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					>A> NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					>A> NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					>A> NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					>A> NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					>A> NPP	Jul 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607	001				PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607	002				PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607	003				PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411	001	>A> 8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411	002	>A> 8133893	Mar 13, 2029	DS DP		
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048	001	>A> 8128960	Dec 17, 2029	DP		
<u>VISMODEGIB - ERIVEDGE</u>						
N203388	001				NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991	001	8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023	U-892		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>